Increase of endocan, a new marker for inflammation and endothelial dysfunction, in acute kidney injury.

Acute kidney injury endocan or endothelial cell-specific molecule 1 (ESM 1) vitamin D

Journal

Northern clinics of Istanbul
ISSN: 2536-4553
Titre abrégé: North Clin Istanb
Pays: Turkey
ID NLM: 101684520

Informations de publication

Date de publication:
2019
Historique:
received: 06 09 2017
accepted: 07 04 2018
entrez: 13 7 2019
pubmed: 13 7 2019
medline: 13 7 2019
Statut: epublish

Résumé

In this study, the clinical relevance of the levels of serum endocan and 25-hydroxyvitamin D [25(OH)D] was investigated in patients with acute kidney injury (AKI). Endocan or the endothelial cell-specific molecule 1 is a soluble proteoglycan secreted by vascular endothelial cells. It plays a significant role in immunity, inflammation, and endothelial function. A total of 39 patients with AKI (19 females, 20 males) and 38 healthy individuals (18 females, 20 males) were included in the study. The levels of serum endocan, vitamin D, and other biochemical parameters were compared between the two groups. In the AKI group, the values of serum creatinine, endocan, parathormone, phosphorus, and uric acid were found to be higher, and the total protein, albumin, and calcium levels were lower compared to the control group. There was no difference between the two groups in terms of the serum vitamin D, magnesium, alkaline phosphatase, and gamma-glutamyl transferase. In patients with AKI, an increased endocan level is a significant marker of inflammation and endothelial injury. In addition, these patients experience vitamin D deficiency.

Identifiants

pubmed: 31297477
doi: 10.14744/nci.2018.70446
pii: NCI-6-124
pmc: PMC6593909
doi:

Types de publication

Journal Article

Langues

eng

Pagination

124-128

Déclaration de conflit d'intérêts

Conflict of Interest: The authors stated that there are no conflicts of interest regarding the publication of this article.

Références

JPEN J Parenter Enteral Nutr. 2004 May-Jun;28(3):133-41
pubmed: 15141404
Am J Physiol Renal Physiol. 2005 Jul;289(1):F8-28
pubmed: 15951480
Biochim Biophys Acta. 2006 Jan;1765(1):25-37
pubmed: 16168566
J Immunol. 2006 Mar 1;176(5):3108-14
pubmed: 16493070
Immunology. 1991 Aug;73(4):466-71
pubmed: 1655638
J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):487-90
pubmed: 17197169
J Am Soc Nephrol. 2007 Feb;18(2):613-20
pubmed: 17202417
Toxicology. 2008 Mar 20;245(3):182-93
pubmed: 18294749
Nephron Clin Pract. 2008;109(4):c192-7
pubmed: 18802367
Kidney Int. 2011 Feb;79(3):288-99
pubmed: 20927041
J Am Soc Nephrol. 2011 May;22(5):810-20
pubmed: 21493774
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
J Clin Invest. 2011 Nov;121(11):4210-21
pubmed: 22045571
Urology. 2012 Sep;80(3):738.e1-8
pubmed: 22608803
Crit Care Med. 2012 Dec;40(12):3170-9
pubmed: 22975885
Clin Endocrinol (Oxf). 2013 Oct;79(4):491-8
pubmed: 23414198
Ren Fail. 2013;35(4):579-91
pubmed: 23472851
Angiology. 2014 Oct;65(9):773-7
pubmed: 24402320
Transplant Proc. 2014;46(2):323-7
pubmed: 24655954
Kidney Int. 2014 Dec;86(6):1213-20
pubmed: 24988065
PLoS One. 2014 Sep 15;9(9):e107228
pubmed: 25222475
J Clin Hypertens (Greenwich). 2014 Dec;16(12):914-6
pubmed: 25376269
Kidney Int. 2014 Dec;86(6):1079-81
pubmed: 25427083
J Nephrol. 2015 Dec;28(6):709-16
pubmed: 25700932
Physiol Rep. 2015 Mar;3(3):null
pubmed: 25780095
Atherosclerosis. 2015 Nov;243(1):339-43
pubmed: 26448266
Clin Chim Acta. 2016 Jan 30;453:1-12
pubmed: 26656443
Kidney Res Clin Pract. 2016 Sep;35(3):152-9
pubmed: 27668158
J Adv Res. 2017 Sep;8(5):529-536
pubmed: 28748118
Miner Electrolyte Metab. 1998;24(4):220-6
pubmed: 9554560

Auteurs

Murat Gunay (M)

Department of Clinical Biochemistry, Erzincan University Faculty of Medicine, Erzincan, Turkey.

Cuma Mertoglu (C)

Department of Clinical Biochemistry, Erzincan University Faculty of Medicine, Erzincan, Turkey.

Classifications MeSH